JP7411631B2 - インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物 - Google Patents
インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物 Download PDFInfo
- Publication number
- JP7411631B2 JP7411631B2 JP2021502998A JP2021502998A JP7411631B2 JP 7411631 B2 JP7411631 B2 JP 7411631B2 JP 2021502998 A JP2021502998 A JP 2021502998A JP 2021502998 A JP2021502998 A JP 2021502998A JP 7411631 B2 JP7411631 B2 JP 7411631B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- disease
- dihydro
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| US62/701,358 | 2018-07-20 | ||
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021530536A JP2021530536A (ja) | 2021-11-11 |
| JP2021530536A5 JP2021530536A5 (https=) | 2022-07-25 |
| JPWO2020018970A5 JPWO2020018970A5 (https=) | 2022-07-25 |
| JP7411631B2 true JP7411631B2 (ja) | 2024-01-11 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502998A Active JP7411631B2 (ja) | 2018-07-20 | 2019-07-19 | インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (https=) |
| EP (1) | EP3823726A1 (https=) |
| JP (1) | JP7411631B2 (https=) |
| KR (1) | KR20210034588A (https=) |
| CN (1) | CN112437683A (https=) |
| AR (1) | AR117617A1 (https=) |
| AU (1) | AU2019305095A1 (https=) |
| BR (1) | BR112021001012A2 (https=) |
| CA (1) | CA3104199A1 (https=) |
| CL (1) | CL2021000152A1 (https=) |
| CO (1) | CO2021000817A2 (https=) |
| CR (1) | CR20210024A (https=) |
| IL (1) | IL280139A (https=) |
| MA (1) | MA53170A (https=) |
| MX (1) | MX2021000660A (https=) |
| PE (1) | PE20211049A1 (https=) |
| PH (1) | PH12020552155A1 (https=) |
| SG (1) | SG11202012159TA (https=) |
| TW (1) | TW202019937A (https=) |
| WO (1) | WO2020018970A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| AU2021291065B2 (en) * | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| WO2023158824A1 (en) * | 2022-02-21 | 2023-08-24 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511200A (ja) | 1997-01-29 | 2000-08-29 | ファイザー・インク | スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用 |
| WO2017140778A1 (en) | 2016-02-16 | 2017-08-24 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| JP2018510207A (ja) | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| JP2020505381A (ja) | 2017-01-23 | 2020-02-20 | ジェネンテック， インコーポレイテッド | インターロイキン−１活性の阻害剤としての化学化合物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| JP2005510542A (ja) | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| ES2600355T3 (es) * | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11339136B2 (en) | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP2020531435A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| EP3668601A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| US20210122739A1 (en) | 2017-08-15 | 2021-04-29 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| AU2019299444A1 (en) | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| TWI811400B (zh) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko not_active Withdrawn
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en not_active Ceased
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es not_active Application Discontinuation
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511200A (ja) | 1997-01-29 | 2000-08-29 | ファイザー・インク | スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用 |
| JP2018510207A (ja) | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| WO2017140778A1 (en) | 2016-02-16 | 2017-08-24 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| JP2020505381A (ja) | 2017-01-23 | 2020-02-20 | ジェネンテック， インコーポレイテッド | インターロイキン−１活性の阻害剤としての化学化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021530536A (ja) | 2021-11-11 |
| TW202019937A (zh) | 2020-06-01 |
| IL280139A (en) | 2021-03-01 |
| PE20211049A1 (es) | 2021-06-04 |
| CL2021000152A1 (es) | 2021-07-09 |
| CR20210024A (es) | 2021-02-22 |
| US20210261568A1 (en) | 2021-08-26 |
| MX2021000660A (es) | 2021-03-25 |
| KR20210034588A (ko) | 2021-03-30 |
| CN112437683A (zh) | 2021-03-02 |
| BR112021001012A2 (pt) | 2021-04-20 |
| US11560391B2 (en) | 2023-01-24 |
| AU2019305095A1 (en) | 2020-12-17 |
| AR117617A1 (es) | 2021-08-18 |
| CA3104199A1 (en) | 2020-01-23 |
| EP3823726A1 (en) | 2021-05-26 |
| SG11202012159TA (en) | 2021-01-28 |
| MA53170A (fr) | 2021-05-26 |
| WO2020018970A1 (en) | 2020-01-23 |
| PH12020552155A1 (en) | 2021-07-05 |
| CO2021000817A2 (es) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7411631B2 (ja) | インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物 | |
| TWI825134B (zh) | 作為介白素-1活性之抑制劑之磺醯脒（sulfonimidamide）化合物 | |
| JP6924267B2 (ja) | ピロロ［１，２−ｂ］ピリダジン誘導体 | |
| TWI789401B (zh) | 新穎化合物 | |
| JP6663857B2 (ja) | ピラゾロピリジンおよびピラゾロピリミジン | |
| CA2886263C (en) | Heteroaryl inhibitors of pde4 | |
| US8545897B2 (en) | Pyrrolopyridines as kinase inhibitors | |
| JP2023055855A (ja) | 新規なスルホンアミドカルボキサミド化合物 | |
| CN112888675A (zh) | 新型磺酰脲化合物 | |
| JP2022502476A (ja) | インドールａｈｒ阻害剤およびその使用 | |
| JP2023542205A (ja) | 新規化合物 | |
| US11878965B2 (en) | Inhibitors of peptidylarginine deiminases | |
| TW201249825A (en) | Novel compounds | |
| HK40040939A (en) | Sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| RU2820289C2 (ru) | Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1 | |
| HK40052548A (en) | Novel sulfoneurea compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220714 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230629 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231225 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7411631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |